연구동향 분석

Physiologically based pharmacokinetic modeling of metoprolol in different CYP2D6 genotypes

Lee, Choongmin 2020년

논문상세정보
인용/피인용
' Physiologically based pharmacokinetic modeling of metoprolol in different CYP2D6 genotypes' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • PBPK Modeling
  • Pharmacokinetics
  • cyp2d6
  • metoprolol
  • pharmacogenomics
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
87 0

0.0%

' Physiologically based pharmacokinetic modeling of metoprolol in different CYP2D6 genotypes' 의 참고문헌

  • Whole body physiologically-based pharmacokinetic models : their use in clinical drug development
    4 ( 9 ) :1143-1152 . [2008]
  • Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination
    93 ( 6 ) :1628-1640 [2004]
  • U.S. Department of Health and Human Services, FDA. (2018) Bioanalytical Method Validation Guidance for Industry. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf
  • The molecular biology of cytochrome P450s
    40 ( 4 ) :243-288 . [1988]
  • The expanding role of quantitative structure-activity relationships ( QSAR ) in toxicology
    79 ( 1-3 ) :45-53 . [1995]
  • The effect of mirabegron , a potent and selective beta3-adrenoceptor agonist , on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol
    pharmacokinetics 39 ( 1 ) :43-52 . [2014]
  • The Biopharmaceutics Classification System ( BCS ) Guidance
    https : //www.fda.gov/media/70963/download [2017]
  • Standard liver volume in the Caucasian population
    5 ( 5 ) :366-368 [1999]
  • Simultaneous determination of metoprolol and its metabolites , alpha-hydroxymetoprolol and O-desmethylmetoprolol , in human plasma by liquidChromatography with tandem mass spectrometry : Application to the pharmacokinetics of metoprolol associated withCYP2D6 genotypes
    37 ( 11 ) :1256-1264 [2014]
  • Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP. (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. The Journal of pharmacology and experimental therapeutics 270(1):414-423.
  • Sequence-basedCYP2D6 genotyping in the Korean population
    28 ( 3 ) :382-387 [2006]
  • Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations .
    1 ( 2 ) : E14 . [2000]
  • Risperidone metabolism in relation toCYP2D6 * 10 allele in Korean schizophrenic patients
    57 ( 9 ) :671-675 . [2001]
  • Regioand Stereo-Selective Oxidation of aCardiovascular Drug , Metoprolol , Mediated byCytochrome P450 2D and 3A Enzymes in Marmoset Livers
    45 ( 8 ) :896-899 . [2017]
  • Proceedings : Relationship between the pharmacokinetic and pharmacodynamic properties of the beta-receptor antagonists alprenolol and metoprolol .
    11 ( 6 ) :660 . [1974]
  • Probing the world ofCytochrome P450 enzymes .
    4 ( 3 ) :157-162 . [2004]
  • Prediction of pharmacokinetics prior to in vivo studies . II . Generic physiologically based pharmacokinetic models of drug disposition
    91 ( 5 ) :1358-1370
  • Prediction of pharmacokinetics prior to in vivo studies . 1 . Mechanism-based prediction of volume of distribution
    91 ( 1 ) :129-156
  • Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic ( PBPK ) modeling approach : ACase study ofCaffeine andCiprofloxacin
    21 ( 1 ) :107-115 . [2017]
  • Predicting the effect ofCytochrome P450 inhibitors on substrate drugs : analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration
    54 ( 1 ) :117-127 . [2015]
  • Physiology-based pharmacokinetic modeling : ready to be used .
    2 ( 1 ) :125-132 . [2005]
  • Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
    51 ( 1 ) :45-73 . [2011]
  • Physiologically based pharmacokinetics ( PBPK )
    41 ( 3 ) :391-407 . [2009]
  • Physiologically based pharmacokinetic modelling of atomoxetine with regard toCYP2D6 genotypes
    8 ( 1 ) :12405 . [2018]
  • Physiologically based pharmacokinetic modelling 2 : predicting the tissue distribution of acids , very weak bases , neutrals and zwitterions
    95 ( 6 ) :1238-1257 . [2006]
  • Physiologically based pharmacokinetic modeling to predictComplex drug-drug interactions : aCase study of AZD2327 and its metabolite ,Competitive and time-dependentCYP3A inhibitors
    36 ( 8 ) :507-519 . [2015]
  • Physiologically based pharmacokinetic modeling in drug discovery and development : A pharmaceutical industry perspective
    97 ( 3 ) :247-262 [2015]
  • Physiologically based pharmacokinetic modeling for sequential metabolism : effect ofCYP2C19 genetic polymorphism onClopidogrel andClopidogrel active metabolite pharmacokinetics
    43 ( 4 ) :510-522 . [2015]
  • Pharmacokinetics of metoprolol in patients with hepatic cirrhosis
    6 ( 5 ) :375-388 . [1981]
  • Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes
    65 ( 4 ) :402-407 . [1999]
  • PharmaVar )
    https : //www.pharmvar.org/
  • PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways
    95 ( 5 ) :550-557 . [2014]
  • Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach
    42 ( 3 ) :383-396 . [2017]
  • Open Systems Pharmacology Suite Manual
    https : //github.com/Open-Systems-Pharmacology/OSPSuite.Documentation [2017]
  • Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women .
    313 ( 3 ) :1172-1181 . [2005]
  • Metoprolol Therapy and CYP2D6 Genotype . In Medical Genetics Summaries , Pratt V , H McLeod , W Rubinstein , L Dean , B Kattman , and A Malheiro , eds . ( Bethesda ( MD ) : National Center for Biotechnology Information ( US )
    [2012]
  • Metoprolol : a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris
    14 ( 5 ) :321-348 . [1977]
  • Metabolism of metoprolol- ( 3-h ) in man , the dog and the rat
    36 ( Suppl 5 ) :125-135 . [1975]
  • Mechanistic approaches to volume of distribution predictions : understanding the processes
    24 ( 5 ) :918-933 [2007]
  • Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment
    131 ( 2 ) :455-461 . [2012]
  • LOPRESSOR HCT ( metoprolol tartrate ) tablet
    https : //www.accessdata.fda.gov/drugsatfda_docs/label/2008/017963s062,018704s021lbl.pdf [2008]
  • Integrated cytochrome P450 reaction phenotyping : attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes .
    57 ( 5 ) :465-480 . [1999]
  • Influence of cytochrome P450 polymorphisms on drug therapies : pharmacogenetic , pharmacoepigenetic and clinical aspects
    116 ( 3 ) :496-526 . [2007]
  • Influence of chronic renal failure on stereoselective metoprolol metabolism in hypertensive patients
    45 ( 12 ) :1422-1433 [2005]
  • Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine , alone and in combination
    36 ( 6 ) :531-538 [1993]
  • Influence of CYP2D6 * 10 on the pharmacokinetics of metoprolol in healthy Korean volunteers
    33 ( 5 ) :567-573 . [2008]
  • Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects .
    72 ( 4 ) :429-437 . [2002]
  • Implications of polymorphic cytochrome p450-dependent drug metabolism for drug development
    29 ( 4 Pt 2 ) :570-573 [2001]
  • Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics .
    76 ( 4 ) :302-312 . [2004]
  • Impact of pharmacometrics on drug approval and labeling decisions : a survey of 42 new drug applications
    7 ( 3 ) : E503-512 . [2005]
  • Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol : a prospective clinical study
    78 ( 4 ) :378-387 . [2005]
  • Human drug metabolising cytochrome P450 enzymes : properties and polymorphisms .
    369 ( 1 ) :89-104 . [2004]
  • High Frequency of CYP2D6 Ultrarapid Metabolizer Genotype in the Finnish Population
    119 ( 3 ) :291-296 . [2016]
  • Guideline on Bioanalytical Method Validation
    [2013]
  • Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users
    85 ( 1 ) :45-50 . [2009]
  • Genetic variation in metabolizing enzyme and transporter genes : comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans
    50 ( 8 ) :929-940 [2010]
  • Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes
    226 ( 2 ) :327-338 . [1999]
  • Genetic analysis of the Chinese cytochrome P4502D locus : characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation
    46 ( 3 ) :452-459 . [1994]
  • General approach for the calculation of tissue to plasma partition coefficients
    22 ( 2 ) :457-467 [2008]
  • G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese .
    27 ( 3 ) :385-388 . [1999]
  • Extension of a pilot study : impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness
    20 ( 2 ) :246-251 [2000]
  • Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans , part 1 : oral solutions
    100 ( 12 ) :5324-5345 [2011]
  • Estimating the water solubilities of crystalline compounds from their chemical structures alone
    41 ( 5 ) :1355-1359 [2001]
  • Enantioselective and diastereoselective aspects of the oxidative metabolism of metoprolol
    40 ( 7 ) :1637-1644 . [1990]
  • Effects of imatinib ( Glivec ) on the pharmacokinetics of metoprolol , a CYP2D6 substrate , in Chinese patients with chronic myelogenous leukaemia
    65 ( 6 ) :885-892 . [2008]
  • Effect of the CYP2D6 * 10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers
    47 ( 4 ) :450-453 [1999]
  • DrugBank metoprolol. https://www.drugbank.ca/drugs/DB00264
  • Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans
    37 ( 7 ) :1464-1470 . [2009]
  • Differences in the Epigenetic Regulation of Cytochrome P450 Genes between Human Embryonic Stem Cell-Derived Hepatocytes and Primary Hepatocytes
    10 ( 7 ) : e0132992 . [2015]
  • Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs
    34 ( 3 ) :401-431 . [2007]
  • DNA microarray technology in the clinical environment : the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping
    14 ( 1 ) :19-34 . [2009]
  • Cytochromes P450 : History , Classes , Catalytic Mechanism , and Industrial Application
    105 ( 105-126 [2016]
  • Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug
    [2018]
  • Cytochrome P450 2D6 : overview and update on pharmacology , genetics , biochemistry . Naunyn-Schmiedeberg 's archives of pharmacology
    369 ( 1 ) :23-37 . [2004]
  • Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines
    16 ( 8 ) :1199-1205 . [1999]
  • Comparative research on the metabolism of metoprolol by four CYP2D6 allelic variants in vitro with LC-MS/MS .
    [2019]
  • Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2 , CYP2C9 , CYP2C19 , CYP2D6 and CYP3A5 in the Japanese population
    12 ( 1 ) :78-82 . [2015]
  • Clinical pharmacokinetics of metoprolol
    5 ( 6 ) :557-569 . [1980]
  • Chemaxon. https://chemaxon.com/products/calculators-and-predictors#pka
  • Calculation of standard liver volume in Korean adults with analysis of confounding variables
    19 ( 4 ) :133-138 [2015]
  • CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection
    55 ( 8 ) :1546-1554 . [2009]
  • CYP2D6 allele frequencies in Korean population ,Comparison with East Asian ,Caucasian and African populations , and theComparison of metabolic activity
    Arch Pharm Res 41 ( 9
  • Binding of adrenergic beta-receptor antagonists to human serum albumin .
    11 ( 4 ) :325-332 . [1974]
  • Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment
    26 ( 8 ) :1007-1013 . [2011]
  • Application of in vitro-in vivo extrapolation ( IVIVE ) and physiologically based pharmacokinetic ( PBPK ) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure
    69 ( 6 ) :1311-1320 . [2013]
  • Application of PBPK modelling in drug discovery and development at Pfizer . Xenobiotica ; the fate of foreign compounds in biological systems
    42 ( 1 ) :94-106 . [2012]
  • Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics : strategy and approach during the drug discovery phase with four case studies
    33 ( 2 ) :85-98 [2012]
  • Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation
    12 ( 1 ) : e0169233 [2017]
  • Affimetrix Human Gene chip U133A from Arrayexpress in database E-GEOD-2361. https://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-2361/
  • Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
    95 ( 23 ) :1758-1764 . [2003]
  • 2005b ) Tissue distribution of basic drugs : accounting for enantiomeric , compound and regional differences amongst beta-blocking drugs in rat
    94 ( 6 ) :1237-1248 .
  • 2005a ) Physiologically based pharmacokinetic modeling 1 : predicting the tissue distribution of moderate-to-strong bases .
    94 ( 6 ) :1259-1276 .